<DOC>
	<DOCNO>NCT01661088</DOCNO>
	<brief_summary>The investigator hypothesize combination FOLFIRINOX regimen ( combination 5-fluorouracil , irinotecan oxaliplatin chemotherapy ) provide maximal systemic disease control FDR-gemcitabine chemotherapy concurrent IMRT ( Radiation therapy ) address local disease , achieve significant improvement R0 resection ( Radiation oncology repeat surgery ) rate borderline resectable ( surgical ) pancreatic cancer enhance disease free overall survival patient population .</brief_summary>
	<brief_title>A Study Neoadjuvant FOLFIRINOX FDR-Gemcitabine With Concurrent IMRT Patients</brief_title>
	<detailed_description>Gemcitabine cornerstone systemic therapy pancreas cancer past decade . Recently , combination 5-fluorouracil , irinotecan oxaliplatin ( FOLFIRINOX ) report significant efficacy advance pancreatic cancer . Preclinical data suggest synergy irinotecan 5FU well oxaliplatin 5FU . Results phase II trial advance disease report 2005 demonstrate 26 % confirm response rate median overall survival 10.2 month . A follow-up phase III trial compare FOLFIRINOX gemcitabine patient &lt; 75 year age advance pancreatic cancer present ASCO 2010 reveal improvement PFS ( 6.4 vs 3.3 month , p= &lt; .0001 ) improve disease control rate ( CR+PR+SD ) ( 70.2 % vs 50.9 % , p=.0003 ) . The notable result impressive improvement median overall survival FOLFIRINOX compare gemcitabine ( 11.1vs 6.8 month , p-value = &lt; .0001 , HR=.57 ) . The main toxicity grade 3/4 neutropenia ( 45.7 % vs 18.7 % , p=.0001 ) increase risk febrile neutropenia ( 5.4 % vs 0.6 % , p=.009 ) 31 .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients must cytologic histologic confirmation carcinoma arise pancreas . Patients must deem borderline resectable disease radiologic evidence distant metastatic disease prior registration . Specifically , patient must least one designation borderline resectable designation unresectable disease . Patients must life expectancy least 12 week , Zubrod performance status &lt; 1 willing medically able undergo surgical resection . Patients must adequate organ function define follow : absolute neutrophil count &gt; 1500/mm3 , platelet &gt; 100,000/mm3 , serum Cr &lt; 1.5 mg/dl , total bilirubin &lt; 2.0 mg/dl relief biliary obstruction present ( PTC tube endobiliary stent ) . Patients must free active systemic malignancy , ongoing infection , serious uncontrolled , concomitant systemic disorder psychiatric condition would interfere safe delivery protocol therapy . Patients reproductive potential must agree use effective contraceptive method participation trial due unacceptable teratogenic toxicity abdominal radiation cytotoxic chemotherapy . Patients must aware investigational nature therapy provide write informed consent . Patients neuroendocrine tumor exclude . Active systemic malignancy , ongoing infection , serious uncontrolled , concomitant systemic disorder psychiatric condition would interfere safe delivery protocol therapy . Patients preexist peripheral neuropathy &gt; grade 2 ineligible Pregnant nursing woman ineligible . Patients must history previous chemotherapy pancreatic cancer abdominal radiation therapy . Patients may use investigational agent within 4 week prior enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neoadjuvant FOLFIRINOX</keyword>
	<keyword>FDR-Gemcitabine</keyword>
	<keyword>Concurrent</keyword>
	<keyword>IMRT</keyword>
	<keyword>Borderline Resectable Pancreatic Cancer</keyword>
</DOC>